# A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

> **NCT05917470** · PHASE1,PHASE2 · TERMINATED · sponsor: **Oncternal Therapeutics, Inc** · enrollment: 21 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** ONCT-534

## Key facts

- **NCT ID:** NCT05917470
- **Lead sponsor:** Oncternal Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-20
- **Primary completion:** 2024-09-12
- **Final completion:** 2024-09-12
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer.
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05917470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05917470, "A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05917470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*